文章核心观点 - 公司发布了2023年可持续发展报告更新版 [1] - 公司是一家大型能源基础设施和物流公司,在北美拥有广泛的管道、储存、加工等资产 [2][3] 公司概况 - 公司全称为Plains All American Pipeline, L.P.(PAA)和Plains GP Holdings(PAGP) [1][3] - 公司总部位于德克萨斯州休斯顿 [3] - 公司平均每天处理超过800万桶原油和天然气液体 [2] 业务范围 - 公司拥有广泛的管道收集和运输系统 [2] - 公司还拥有码头、储存、加工、分馏等基础设施资产 [2] - 公司的资产主要服务于美国和加拿大的主要产油盆地、运输走廊和主要市场枢纽以及出口点 [2]

CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the second quarter ended June 30, 2024 on Tuesday, August 13, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Tim ...

TORONTO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- New Horizon Aircraft (NASDAQ:HOVR), doing business as Horizon Aircraft ("Horizon Aircraft" or the "Company"), the advanced aerospace engineering company and developer of eVTOL (electric Vertical Take-Off and Landing) aircraft, publishes new global research* that indicates fund managers that invest primarily in small-cap and micro-cap stocks believe there will be an increased level of exposure to small and micro-caps from both institutional and retail investors over ...

Oak Ridge, TN, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces it has been awarded a $1.9M two-year contract from the U.S. Air Force (USAF) to support the continued development of a novel fluorescent tracer and optical sensing technology into a next-generation point-of-care blood volume analyzer for military and civilian applications. Michael Feldschuh, Daxor's President and CEO, highlighted the significance of this ...

Enhances Focus on Returning Capital to Shareholders With Updated Dividend Policy Declares Cash Dividend of $0.25 Per Share reflecting strong financial results | --- | --- | --- | --- | --- | --- | |-----------------------------------------|---------|---------|-------|---------|---------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Highlights (in million USD, except EPS) | Q2 2024 | Q2 2023 | | 6M 2024 | 6M 2023 | | | | | | | | | Net Revenues | $43.1 | $28.3 | $81.4 | | $46.4 | | ...

文章核心观点 - 公司宣布派发每股0.04美元的定期现金股利,将于2024年9月2日支付给2024年8月19日登记在册的股东[1] 公司概况 - 公司主要从事海洋和重型非公路动力传动设备的设计、制造和销售[2] - 产品包括海洋变速箱、方位驱动装置、表面驱动装置、螺旋桨和船舶管理系统,以及动力换挡变速箱、液压扭矩转换器、动力输出装置、工业离合器和控制系统[2] - 公司的客户主要集中在休闲船艇、商业和军事海事市场,以及能源和自然资源、政府和工业市场[2] - 公司通过直销团队和分销网络在全球范围内开展业务[2]

MALVERN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced new preclinical data demonstrating the synergistic effect of its lead compound, buntanetap, when combined with the glucagon-like peptide 1 (GLP-1) agonist dulaglutide (Trulicity®) in a mouse model of Alzh ...

MORRISVILLE, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, today announced the grand opening of its new, 19,000-square-foot corporate headquarters in Morrisville, North Carolina, in the heart of Research Triangle Park. The new, state-of-the-art facility, will serve as a hub for all Science 37 operations, enabling cross-functional teams with greater opportunities for collaborative problem-solving and integrated solution delivery. Centralizing ope ...

Completed enrollment of the planned 150 patients in COMPANION-002, a Phase 2/3 trial of CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced Metastatic or Recurrent Biliary Tract Cancers (BTC) Approved an Investigator Sponsored Trial (IST) of CTX-009 in the first-line setting in patients with Biliary Tract Cancer BOSTON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company deve ...

CUPERTINO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- -Similar patent has also been granted in Japan -Brilaroxazine has received Orphan Drug Designation for the treatment of idiopathic pulmonary fibrosis (IPF) Cupertino, Calif., August 6, 2024 – Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, ...